No­var­tis CEO takes pay cut as Ab­b­Vie's Rick Gon­za­lez nabs near­ly 10% raise

Two CEOs are look­ing at no­tice­ably dif­fer­ent com­pen­sa­tion pack­ages this year when com­pared to last year.

No­var­tis CEO Vas Narasimhan, who re­cent­ly took over as chair of the PhRMA board, last year brought home 8.4 mil­lion Swiss francs ($9 mil­lion), which was a 25% de­crease from a year pri­or, when he col­lect­ed 11.2 mil­lion Swiss francs ($12 mil­lion).

Ab­b­Vie CEO Rick Gon­za­lez, on the oth­er hand, who saw his com­pa­ny ex­it PhRMA and oth­er in­dus­try trade groups in 2022, capped his fi­nal year of the com­pa­ny’s mon­u­men­tal Hu­mi­ra mo­nop­oly, and earned a raise to $26.2 mil­lion in com­pen­sa­tion, up from $23.9 mil­lion in 2021 and $24 mil­lion in 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER